Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743580 | 0.92 | MAP3K5 (0.39) | MAP3K5LRRK2TYRRXFP1KDM4E | |
| SCHEMBL2743588 | 0.88 | HDAC3 (0.44) | MAP3K5LRRK2TYRKDM4EMEN1 | |
| SCHEMBL2743905 | 0.85 | MAP3K5 (0.45) | MAP3K5LRRK2TYRRXFP1MEN1 | |
| SCHEMBL2743490 | 0.84 | SCD (0.45) | MAP3K5LRRK2TYRRXFP1ALDH1A1 | |
| SCHEMBL2743488 | 0.83 | SMN1; SMN2 (0.48) | MAP3K5LRRK2TYRL3MBTL1RAB9A | |
| SCHEMBL2743511 | 0.82 | LRRK2 (0.55) | MAP3K5LRRK2KDM4EALDH1A1SCD | |
| SCHEMBL2743373 | 0.81 | MAPT (0.45) | MAP3K5LRRK2TYRKDM4EALDH1A1 | |
| SCHEMBL2743593 | 0.81 | MAP3K5 (0.42) | MAP3K5LRRK2TYRRXFP1KDM4E | |
| SCHEMBL2743929 | 0.81 | MAP3K5 (0.42) | MAP3K5LRRK2TYRRXFP1KDM4E | |
| SCHEMBL2743432 | 0.80 | MAP3K5 (0.37) | MAP3K5LRRK2TYRRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178555-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | claimed |
| WO-2010008843-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | claimed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | claimed |
| US-8178555-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178555-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178555-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2010008843-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | HPGDS 1211/4885MAP3K5 8/4885LRRK2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.